SAVA * Stock Overview
A clinical stage biotechnology company, develops drugs for neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cassava Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$89.00 |
| 52 Week High | US$650.00 |
| 52 Week Low | US$85.00 |
| Beta | -0.58 |
| 11 Month Change | -82.45% |
| 3 Month Change | -84.94% |
| 1 Year Change | n/a |
| 33 Year Change | -91.72% |
| 5 Year Change | n/a |
| Change since IPO | -91.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| SAVA * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | -83.3% | -2.1% | -0.9% |
| 1Y | n/a | -17.9% | -4.1% |
Return vs Industry: Insufficient data to determine how SAVA * performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SAVA * performed against the MX Market.
Price Volatility
| SAVA * volatility | |
|---|---|
| SAVA * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.2% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: SAVA *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine SAVA *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 29 | Rick Barry | www.cassavasciences.com |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. Fundamentals Summary
| SAVA * fundamental statistics | |
|---|---|
| Market cap | Mex$4.27b |
| Earnings (TTM) | -Mex$365.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.4x
P/E RatioIs SAVA * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAVA * income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$67.84m |
| Gross Profit | -US$67.84m |
| Other Expenses | -US$50.17m |
| Earnings | -US$17.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SAVA * perform over the long term?
See historical performance and comparison